In this study, we discuss the efficacy of osimertinib as a second-line treatment in patients, especially BM patients, with EGFR T790M-positive advanced NSCLC who experience disease progression with prior first-generation EGFR-TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.